Literature DB >> 2788651

Attenuated processing of epidermal growth factor in the face of marked degradation of transforming growth factor-alpha.

M Korc1, J E Finman.   

Abstract

T3M4 human pancreatic carcinoma cells avidly bound and internalized 125I-labeled epidermal growth factor (EGF) but did not readily degrade the ligand. Pulse-chase experiments in which the cell-bound radioactivity was allowed to dissociate into the incubation medium in the presence of unlabeled EGF indicated that the majority of the released 125I-EGF consisted of intact EGF and a slightly processed species that readily bound to the cell. Omission of unlabeled EGF during the chase period markedly decreased the amount of radioactivity in the incubation medium, mainly as a result of the rebinding of EGF to the cells. In contrast, T3M4 cells readily degraded 125I-labeled transforming growth factor-alpha (TGF-alpha), and the released radiolabeled products did not rebind to the cells. Both ligands were released from T3M4 cells under acidic conditions, complete dissociation occurring at a pH of 4.5 for EGF, and a pH of 6.5 for TGF-alpha. A 431 human epidermoid carcinoma cells and ASPC-1 human pancreatic carcinoma cells also failed to extensively degrade 125I-EGF, whereas Rat-1 fibroblasts markedly degraded the growth factor. As in the case of T3M4 cells, ASPC-1 cells extensively degraded 125I-TGF-alpha. Degradation of either ligand was blocked by the lysosomotropic compound methylamine in all the tested cell lines. Immunoprecipitation of the EGF receptor with specific polyclonal antibodies and Western blot analysis revealed the anticipated 170-kDa protein in T3M4 cells. Both EGF and TGF-alpha enhanced EGF receptor degradation, but TGF-alpha was less effective than EGF. These findings indicate that in certain cell types EGF and TGF-alpha may be differentially processed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2788651

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  Release and binding of epidermal growth factor in the pancreas of rats.

Authors:  J Jaworek; S J Konturek; W Bielanski; J Bilski; M Hladij
Journal:  Int J Pancreatol       Date:  1992-02

2.  Endosomal receptor kinetics determine the stability of intracellular growth factor signalling complexes.

Authors:  A Rami Tzafriri; Elazer R Edelman
Journal:  Biochem J       Date:  2007-03-15       Impact factor: 3.857

3.  Epidermal growth factor and transforming growth factor-alpha: differential intracellular routing and processing of ligand-receptor complexes.

Authors:  R Ebner; R Derynck
Journal:  Cell Regul       Date:  1991-08

4.  Comparative mitogenic potencies of EGF and TGF alpha and their dependence on receptor-limitation versus ligand-limitation.

Authors:  C C Reddy; A Wells; D A Lauffenburger
Journal:  Med Biol Eng Comput       Date:  1998-07       Impact factor: 2.602

Review 5.  Potential role of the epidermal growth factor receptor in human pancreatic cancer.

Authors:  M Korc
Journal:  Int J Pancreatol       Date:  1990 Aug-Nov

6.  Fates of endocytosed somatostatin sst2 receptors and associated agonists.

Authors:  J A Koenig; R Kaur; I Dodgeon; J M Edwardson; P P Humphrey
Journal:  Biochem J       Date:  1998-12-01       Impact factor: 3.857

7.  Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers.

Authors:  A E Lenferink; R Pinkas-Kramarski; M L van de Poll; M J van Vugt; L N Klapper; E Tzahar; H Waterman; M Sela; E J van Zoelen; Y Yarden
Journal:  EMBO J       Date:  1998-06-15       Impact factor: 11.598

Review 8.  Pancreatic cancer: the potential clinical relevance of alterations in growth factors and their receptors.

Authors:  H Friess; P Berberat; M Schilling; J Kunz; M Korc; M W Büchler
Journal:  J Mol Med (Berl)       Date:  1996-01       Impact factor: 4.599

9.  Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha.

Authors:  M Korc; B Chandrasekar; Y Yamanaka; H Friess; M Buchier; H G Beger
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

10.  A variant epidermal growth factor receptor exhibits altered type alpha transforming growth factor binding and transmembrane signaling.

Authors:  T Moriai; M S Kobrin; C Hope; L Speck; M Korc
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.